Spending for prescription and over-the-counter pharmaceutical products totaled $413 billion in 2012 according to the Bureau of Economic Analysis’ (BEA) trade and transports margin data. Just over half of this spending (52%) accrued to the pharmaceutical companies that produced the medicines, while the remainder was divided between transport and wholesale margins (21%) and retail margins (26%).
Compared to other research and development (R&D)-intensive manufacturing industries with significant consumer sales, the pharmaceutical and medicines manufacturing industry ranks second in terms of R&D intensity behind communications equipment, and receives the second lowest producers’ share of total spending after other miscellaneous manufacturing. Thus, the pharmaceutical industry is unique among manufacturing industries in that it devotes a large share of its revenue to R&D, despite receiving a considerably smaller share of total spending.
Read the report
You may be interested in
Australia: RBA hike by another 25 bps as the fight against inflation continues
The RBA has raised its cash rate target by a further 25 basis points, taking it to 4.1%. Although inflation has peaked, the RBA board is still clearly uncomfortable with its brisk pace.Find Out More
BIS Oxford Economics to be rebranded as Oxford Economics Australia
Over the past six years we've maintained the unique modelling and analysis that clients and the media have come to rely on from BIS Shrapnel while incorporating Oxford Economics' rigorous global modelling and analytical framework to complement it," said David Walker, Director, Oxford Economics Australia.Find Out More
Introducing our renovated African Forecasting Service
From economy to politics, investment to operation, fuel your business growth by leveraging our complete Africa solutions.Find Out More